Discovery of Inhibitors for the Ether Lipid-Generating Enzyme AGPS as Anti-Cancer Agents

Area of Science:

• Biochemistry
• Oncology
• Medicinal Chemistry

Background:

• Dysregulated ether lipid metabolism is a key characteristic of cancer cells.
• Alkyl-glycerone phosphate synthase (AGPS) is vital for ether lipid generation and is implicated in cancer pathogenicity.
• Targeting AGPS may offer a novel therapeutic strategy for cancer treatment.

Purpose of the Study:

• To identify small-molecule inhibitors of AGPS through a screening approach.
• To characterize the interaction of identified inhibitors with the AGPS active site.
• To evaluate the efficacy of lead AGPS inhibitors in reducing ether lipid levels and impairing cancer cell functions.

Main Methods:

• Small-molecule screening to identify AGPS inhibitors.
• Structural characterization of enzyme-inhibitor interactions.
• In vitro assessment of lead inhibitor 1a on human cancer cell lines.

Main Results:

• Several lead AGPS inhibitors were identified, binding to distinct sites within the enzyme's active site.
• Lead inhibitor 1a selectively reduced ether lipid levels in various human cancer cell types.
• Inhibitor 1a demonstrated impairment of cancer cell survival and migration.

Conclusions:

• The study reports the first in situ-active pharmacological tools for inhibiting AGPS.
• These identified AGPS inhibitors serve as potential chemical scaffolds for developing future cancer therapeutics.
• Targeting AGPS represents a promising strategy for novel cancer therapy development.